ACR 132 is a nonbinding concurrent resolution that designates February 28, 2026, as Rare Disease Day in California and expresses legislative support for improving awareness, encouraging accurate and early diagnosis, and supporting efforts to develop diagnostics and treatments for rare diseases and disorders. The text compiles federal and state context — from the Orphan Drug Act anniversary to recent FDA and state initiatives — to frame the Legislature’s recognition.
The resolution is ceremonial: it does not create rights, fund new programs, or impose regulatory obligations. Its practical value lies in signaling priorities to state agencies, researchers, patient groups, and the life sciences sector and in consolidating a legislative record that reference bodies and advocates can cite in future policy work.
At a Glance
What It Does
A concurrent resolution that formally recognizes Rare Disease Day and records a series of factual findings about rare diseases and recent federal and state efforts. It asks the Chief Clerk of the Assembly to transmit copies of the resolution but does not create statutory duties or funding.
Who It Affects
Patients with rare diseases and their families, advocacy organizations, academic and commercial life sciences entities in California, health care providers who diagnose and treat rare conditions, and the Jacqueline Marie Zbur Rare Disease Advisory Council referenced in the text.
Why It Matters
Although ceremonial, the resolution aggregates authoritative facts and federal program references that stakeholders can use to press for policy change, funding, or regulatory attention. For public affairs teams and compliance officers in life sciences firms, it is a signal of legislative interest that can influence stakeholder engagement and partnership strategies.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The resolution opens with a set of factual findings: it adopts the U.S. definition of a rare disease (fewer than 200,000 affected individuals), cites a nationwide prevalence figure (more than 30 million Americans living with one of over 10,000 known rare diseases), and notes that children represent a substantial share of those affected. The text underscores the clinical seriousness of many rare conditions and emphasizes diagnostic challenges and gaps in specialist expertise.
ACR 132 records federal and state developments that frame the issue. It marks the 43rd anniversary of the Orphan Drug Act, notes the FDA’s 2022 Accelerating Rare Disease Cures Program, and cites a 2023 federal pilot program to develop novel efficacy endpoints for rare-disease trials.
The resolution also points to California’s 2024 creation of the Jacqueline Marie Zbur Rare Disease Advisory Council and highlights the state’s contribution to rare disease product development—calling out nearly 200 rare-disease drugs and treatments that originated in California.The text also sets out hard numbers to contextualize the policy gap: the FDA has approved more than 1,100 drugs or biologics for orphan indications, yet roughly 90 percent of rare diseases still lack an approved treatment. The resolution lists sample conditions (from sickle cell anemia and spinal muscular atrophy to Batten disease and achondroplasia) to illustrate the variety of rare disorders and to show that the term covers a wide clinical spectrum.Finally, ACR 132 situates the state action in a global awareness effort: it references EURORDIS’s 2008 founding of Rare Disease Day and notes that the observance now involves more than 100 countries.
Procedurally the resolution is short: it designates the date in the legislative record and directs the Assembly’s Chief Clerk to transmit copies for distribution. It does not appropriate funds or direct agencies to implement new programs.
The Five Things You Need to Know
The resolution cites the U.S. statutory threshold for a rare disease: a condition affecting fewer than 200,000 individuals in the United States.
It records a prevalence estimate of more than 30 million Americans living with at least one of the more than 10,000 known rare diseases or disorders.
The text notes that the FDA has approved over 1,100 orphan-designated drugs and biological products but states that about 90% of rare diseases lack an FDA‑approved treatment.
ACR 132 references two federal initiatives: the FDA’s 2022 Accelerating Rare Disease Cures Program and the rare disease endpoint advancement pilot program created in the Consolidated Appropriations Act of 2023.
The resolution cites California’s 2024 establishment of the Jacqueline Marie Zbur Rare Disease Advisory Council and highlights that nearly 200 rare-disease drugs and treatments originated in California.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Definitions, prevalence, and examples
This cluster of WHEREAS clauses sets out the bill’s factual foundation: it adopts the U.S. definition of a rare disease, gives prevalence figures (nationally and in terms of disease count), points out the pediatric share and clinical seriousness of many conditions, and lists specific diseases as examples. Practically, these findings establish the facts the Legislature wants on the record — useful for advocates and agencies seeking legislative support for later actions.
Federal programs and California’s role
These clauses catalog recent federal and state initiatives: the Orphan Drug Act anniversary, FDA programs aimed at speeding rare-disease development, the 2023 pilot for novel efficacy endpoints, and California’s 2024 Jacqueline Marie Zbur Rare Disease Advisory Council. By collecting these items the resolution ties California’s recognition to ongoing regulatory and research activity, signaling continuity with federal efforts rather than creating new policy.
Designation and recognition
The operative clause states the Legislature’s designation of February 28, 2026, as Rare Disease Day and formally recognizes the importance of awareness, accurate and early diagnosis, and support for development of treatments and diagnostics. This is a declaratory act: it expresses legislative priorities but contains no binding directives or funding mechanisms.
Transmittal instruction
The final clause directs the Chief Clerk of the Assembly to transmit copies of the resolution to the author for distribution. This is a routine, technical step that ensures the text reaches stakeholders and becomes part of the legislative record for citation in advocacy or awareness campaigns.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with rare diseases and their families — the resolution raises public and legislative awareness, which advocacy groups can use to press for improved diagnosis, funding, and access to care.
- Patient advocacy organizations — they gain a state-level statement that can amplify awareness campaigns and support fundraising or policy asks.
- California life sciences companies and researchers — the Legislature’s recognition reinforces California’s brand as a rare-disease research hub and can help in public–private partnership discussions.
- Jacqueline Marie Zbur Rare Disease Advisory Council — the council’s existence and work are validated in the legislative record, strengthening its visibility and potential influence.
Who Bears the Cost
- State legislative staff and the Chief Clerk’s office — minor administrative tasks for preparing and distributing copies and maintaining the record, paid from existing legislative resources.
- State agencies and public-health offices that choose to respond — while the resolution doesn’t mandate action, agencies that follow up (awareness campaigns, reporting) will absorb staff time and resources if they undertake activities.
- Health systems and clinicians — potential increases in referrals or diagnostic workups could create short-term capacity pressures in specialty clinics or genetic testing services if awareness activities drive demand.
Key Issues
The Core Tension
The central tension is symbolic recognition versus substantive change: the resolution elevates attention to rare diseases without committing resources or regulatory authority, creating pressure to translate awareness into funding, access, and measurable policy outcomes—choices that require trade-offs among competing budgetary and regulatory priorities.
ACR 132 is explicitly nonbinding and ceremonial, which limits its direct policy impact. That is both a strength — it allows rapid, bipartisan recognition — and a limitation: the resolution collects problems (diagnostic delays, lack of treatments, affordability) but does not authorize funding, regulatory changes, or new programs that would address those gaps.
The document therefore risks raising expectations without providing concrete state-level remedies.
The resolution also bundles diverse conditions under the single label “rare diseases,” which helps unify advocacy but obscures heterogeneity in clinical course, patient needs, and policy solutions. A one-size-fits-all awareness day won’t resolve access differences between an FDA‑approved orphan drug with high cost and a condition with no clinical trial infrastructure.
Finally, the text references federal programs and California’s advisory council but leaves open the question of how those actors should coordinate or how the state will measure progress from awareness to better diagnosis or treatment access.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.